Related Experiment Video
Updated: Mar 25, 2026
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Reanalysis of membranoproliferative glomerulonephritis patients according to the new classification: a multicenter
Sung Ae Woo1, Hye Young Ju2, Soon Hyo Kwon1
1Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.
Insights
Complement-mediated glomerulonephritis, a form of membranoproliferative glomerulonephritis (MPGN), was found in 4.3% of previously diagnosed MPGN patients. This finding aids in understanding MPGN classifications and prognoses.
Area of Science:
- Nephrology
- Immunology
- Pathology
Background:
- Membranoproliferative glomerulonephritis (MPGN) encompasses progressive kidney diseases with poor prognoses.
- A recent classification divides MPGN into immune complex-mediated and complement-mediated categories.
- Investigating C3 glomerulonephritis frequency in MPGN patients is crucial for accurate diagnosis and management.
Purpose of the Study:
- To determine the incidence of complement-mediated MPGN (C3 glomerulonephritis) within a cohort of patients previously diagnosed with MPGN.
- To evaluate the prognostic significance of different MPGN classifications.
Main Methods:
- Retrospective analysis of 3,294 renal biopsy patients from 2001-2010.
- Reclassification of MPGN cases based on the new immune complex- and complement-mediated criteria.
- Assessment of renal dysfunction defined as a 50% GFR reduction or need for renal replacement therapy.
Main Results:
- MPGN was diagnosed in 77 (2.3%) patients; 46 were analyzed after exclusions.
- Complement-mediated MPGN (C3 glomerulonephritis) was identified in 2 patients (4.3%).
- Serum albumin and creatinine levels were identified as risk factors for renal deterioration.
Conclusions:
- Complement-mediated glomerulonephritis accounts for 4.3% of previously diagnosed MPGN cases.
- Accurate classification of MPGN is essential for understanding disease progression and prognosis.
Background:
All types of membranoproliferative glomerulonephritis (MPGN) are progressive diseases with poor prognoses. Recently, a newly proposed classification of these diseases separated them into immune complex- and complement-mediated diseases. We investigated the frequency of C3 glomerulonephritis among previously diagnosed MPGN patients.
Methods:
We conducted a retrospective study of patients diagnosed with MPGN at three tertiary care institutions between 2001 and 2010. We investigated the incidence of complement-mediated disease among patients diagnosed with MPGN. Progressive renal dysfunction was defined as a 50% reduction in the glomerular filtration rate or the need for renal replacement therapy.
Results:
Among the 3,294 renal biopsy patients, 77 (2.3%) were diagnosed with MPGN; 31 cases were excluded, of which seven were diagnosed with systemic lupus nephritis, and the others were not followed for a minimum of 12 months after biopsy. Based on the new classification, complement-mediated MPGN was diagnosed in two patients (4.3%); only one patient developed progressive renal dysfunction. Among the immune complex-mediated MPGN patients, 17 patients developed progressive renal dysfunction. Serum albumin and creatinine levels at the time of MPGN diagnosis were risk factors of renal deterioration, after adjusting for low C3 levels and nephrotic syndrome.
Conclusion:
Complement-mediated glomerulonephritis was present in 4.3% of patients previously diagnosed with MPGN.
More Related Videos
Related Concept Videos
01:26Nephrotic Syndrome II : Assessment and Medical Management
01:24Nephrotic Syndrome I : Introduction
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:28Acute Pyelonephritis II: Diagnostic Studies and Management